What is the recommended comprehensive management for a child with Beckwith‑Wiedemann syndrome, including tumor surveillance, hypoglycemia treatment, cardiac evaluation, and surgical considerations?

Management of Beckwith-Wiedemann Syndrome

Children with Beckwith-Wiedemann syndrome require rigorous tumor surveillance with renal ultrasounds every 3 months through age 7 years and full abdominal ultrasounds plus serum alpha-fetoprotein measurements every 3 months through age 4 years, along with prompt management of neonatal hypoglycemia and macroglossia-related complications. 1

Tumor Surveillance Protocol

Wilms Tumor Screening

• Perform renal ultrasounds (including adrenal glands) every 3 months from birth or diagnosis through the 7th birthday 1
• This frequency is critical because interval tumor development increases significantly when screening intervals exceed 4 months 1
• Approximately 93% of Wilms tumors in BWS occur before age 8 years, with 69% occurring before age 4 years 1
• Early detection through this protocol results in lower-stage tumor detection and significantly improved outcomes 1

Hepatoblastoma Screening

• Perform full abdominal ultrasound plus serum alpha-fetoprotein (AFP) measurements every 3 months from birth through the 4th birthday 1
• After the 4th birthday, transition to renal-only ultrasounds every 3 months until age 7 years 1
• AFP elevation often precedes ultrasound detection of hepatoblastoma, and most hepatoblastomas occur within the first year of life, with the oldest reported at 30 months 1
• BWS patients have a 2,280-fold increased relative risk for hepatoblastoma compared to the general population 1

Specialist Involvement

• Refer patients to cancer predisposition specialists (geneticist or pediatric oncologist) for evaluation and monitoring when possible 1
• Physical examination by specialists should occur twice yearly, including ongoing education about tumor manifestations and reinforcement of screening compliance 1

Important caveat: While European centers have implemented risk-stratified screening based on specific genetic/epigenetic subtypes (IC1 gain of methylation carries 28% tumor risk vs. IC2 loss of methylation at 2.6%), North American guidelines currently recommend uniform screening regardless of molecular subtype 1. This reflects different healthcare environments and represents a broad framework prioritizing early detection over risk stratification 1.

Hypoglycemia Management

Neonatal Period

• Approximately 50% of BWS infants develop hyperinsulinemic hypoglycemia (HH), which is transient in most cases but severe and medically-unresponsive in approximately 5% 2, 3
• Infants with paternal uniparental disomy (pUPD11) of chromosome 11p15 are at highest risk for severe, persistent HH 2
• Initial management includes high-concentration intravenous dextrose, with diazoxide as first-line medical therapy if HH persists beyond 7-10 days 4

Diazoxide Therapy

• Assess diazoxide response after at least 5 days of therapy due to its long half-life (15 ± 5.3 hours) 4
• Diazoxide can be dosed twice or three times daily with equivalent efficacy; once-daily dosing causes significant level variation and is not suitable 4
• For diazoxide-unresponsive cases, consider octreotide infusion or mTOR inhibitors (sirolimus) before proceeding to near-total pancreatectomy 2, 3

Critical pitfall: In BWS patients with perinatal stress, wait 7-10 days before starting diazoxide if glucose levels can be safely maintained >70 mg/dL with IV dextrose, as most perinatal stress HH cases resolve spontaneously 4. Premature diazoxide use in this population carries increased risk of adverse events, including pulmonary hypertension 4.

Surgical Considerations

Macroglossia Management

• Partial glossectomy is indicated for feeding difficulties, speech impairment, or airway compromise 5, 3
• Timing is typically between 2-12 months of age when feeding difficulties become apparent 3
• Tongue reduction surgery with ablation techniques can improve pronunciation and feeding outcomes 6

Abdominal Wall Defects

• Omphalocele repair is required in approximately 34% of BWS patients (16 of 47 in one surgical series) 5
• Surgical repair should be performed in the neonatal period with standard techniques 5

Hemihypertrophy-Related Procedures

• Approximately 15% of BWS patients require surgeries related to hemihypertrophy/lateralized overgrowth 5
• Overall survival is 100% with feeding difficulty (47%) being the most frequent complication across all surgical interventions 5

Cardiac Evaluation

• Screen for cardiac abnormalities including patent ductus arteriosus and arrhythmias 6, 3
• Atrial tachycardia can occur and may be recurrent, requiring electrocardiogram monitoring 6
• Echocardiography should be performed as part of initial evaluation 6

Genetic Counseling

• Refer all families to genetics healthcare professionals for molecular diagnosis, recurrence risk assessment, and family testing 1
• Molecular subtype determination (IC1 gain of methylation, IC2 loss of methylation, pUPD11, CDKN1C mutations, or chromosomal rearrangements) is essential for accurate genetic counseling 1
• Most cases (85%) are not inherited and result from epigenetic changes 1

Additional Tumor Risks

Beyond Wilms tumor and hepatoblastoma, BWS patients have increased risk for neuroblastoma, rhabdomyosarcoma, pheochromocytoma, and adrenocortical carcinoma 1. Patients with CDKN1C mutations specifically require neuroblastoma screening with urine catecholamines and chest radiographs 1.